Form DEFA14A Eliem Therapeutics, Inc.

Related Keywords

Delaware ,United States ,New York ,New Castle County ,Boston ,Massachusetts ,State Of Delaware ,New York Stock Exchange ,California ,Washington ,United Kingdom ,Cambridge ,Cambridgeshire ,America ,American ,Sjogren Maciel ,Wilmer Cutler Pickering Hale ,Aaron Davis ,Srinivas Akkaraju ,Inebilizumab Amgen Tafasitamab Incyte ,Daniels Lyons ,Chris Brinzey ,Nir Messafi ,Christopherd Barnstable Brown ,Asaf Shinar ,Stephen Basil Thomas ,Stephen Thomas ,Chris Barnstable Brown ,Alan Hambleton ,Peter Kolchinsky ,Ryan Sansom ,William Bonificio ,Miguel Vega ,Scott Lunin ,Andrew Levin ,Company Regulated Product ,Leerink Partners ,Company As Parent ,Company Source Code ,Third Party ,Source Initiative ,Company Stockholders For Stock ,Company Termination Fee ,Company Equityholder Representative The ,Companya Determination Notice ,Company Offerings Or Internal Systems ,Affiliate Of The Company ,Company Board ,Organizational Documents Of The Company ,Nasdaq ,Indebtedness Of The Company ,Form Of Company Support Agreement ,Exploitation Of The Company Offerings ,Parent The Company Financial ,Company Equityholder ,Company Or Parent ,Company Knowledge ,Company Owned Intellectual Property ,Exchange Procedures ,Conditions To Obligations Of The Company ,York Stock Exchange ,Company Plan ,Company Regulated Products ,Company Stock Plan ,Group Inc ,Company Equityholders ,Knowledge Of The Company ,A Party ,Company Stock ,Company Transaction Expenses ,Company Of The Transaction ,Ra Capital Nexus Fund ,Tax Returns Of The Company ,Company Common Stock ,Company Covered Person ,Company Registrations ,Amgen ,Ra Capital Healthcare Fund ,Investment Company ,Company Intellectual Property Or ,Company Disclosure Schedule ,Sera Services ,Company Financial Statements ,Company Obligations ,Equity Interests Of The Company ,Payment Fund ,Company In Section ,Company To Parent ,Identifiable Health Information ,European Union ,Health Care Program ,Services Administration ,Company Licensed Intellectual Property ,Nature Of Beneficial Holding ,Company Stockholder Approval ,Company Transitory Subsidiary ,Corporation Law ,Company An Investor Questionnaire ,Regulatory Authority ,Party Consents ,Biotechnology Master Fund Ltd ,None Of The Company ,Party Beneficiaries ,Tax Returns For The Company ,Company Certificate ,Company Intellectual Property Or Offering ,Warranties Of The Company ,Parent Indemnified Party ,Agreements Of The Company ,Tax Return Of The Company ,World Trade Center ,Division Of Corporation ,Effective Time The Company ,Title To Properties ,Health Insurance Portability ,Company Diligence Obligations ,Breach Notification For Unsecured Protected Health Information ,Form Of Company ,Company Safes ,Company Support Agreements ,Neither The Company ,United States District Court ,Company Stockholder Matters ,Securities Exchange ,European Medicines Agency ,Electronic Protected Health Information ,Trust Company ,Organization For Economic Cooperation ,Eliem Therapeutics Inc ,Sera Services Inc ,Company Intellectual Property ,Illustrative Calculation Of Base ,Clearing Corporation ,Company Material Adverse Effect ,Member Of Samsara Biocapital ,Good Laboratory Practices Glps ,Company Voting Proposals ,Company Or Tenet ,Tenet Medicines Inc ,Company Stockholder ,Boxer Capital ,Termination Of Payment Fund ,Certificate Of Incorporation The Surviving Corporation ,Janus Henderson Biotech Innovation Master Fund ,Board Of Directors The Company ,Bylaws Of The Company ,Representative Of The Company ,Exchange Commission ,Course Of Business The Company ,Company On Section ,Trademark Office ,Company As Affiliates ,Treatment Of Company Safes ,Nasdaq Stock Market ,Company Stockholders ,Drug Administration ,Operation Of The Company ,Committee Of The Parent Board Directors ,Us Securities Exchange Commission ,Financial Action Task Force On Money Laundering ,Company Equityholder Representative ,Company Offerings ,Company Offering ,Corporation Certificate Of Incorporation ,Bank Secrecy ,Tango Merger Sub Inc ,Company Financial ,Sera Service Providers ,Public Company Accounting Oversight Board ,Company Support Agreement ,Conversion Of Company Common Stock ,Company Certificate Of Incorporation ,No Affiliate Of The Company ,Exchange Act Of The ,Company Stock Or ,No Further Ownership Rights In Company Stock ,Securities Exchange Act ,Exact Name ,Principal Executive Offices ,Zip Code ,Former Name ,Former Address ,Changed Since Last Report ,General Instruction ,Securities Act ,Exchange Act ,Nasdaq Global Market ,Material Definitive ,Eliem Therapeutics ,Acquisition Agreement ,Tango Merger Sub ,Transitory Subsidiary ,Tenet Medicines ,Aggregate Consideration ,Private Placement ,Special Committee ,Company Voting ,Chief Executive Officer ,Chief Business Officer ,Tenet Support ,Joinder Agreements ,Support Agreements ,Lock Up Agreements ,Securities Purchase Agreement ,Closing Date ,Securities Purchase ,Registration Rights Agreement ,Registrable Holders ,Filing Deadline ,Registration Rights ,Registrable Holder ,Subject Agreements ,Joinder Agreement ,Current Report ,Subject Agreement ,Certain Officers ,Compensatory Arrangements ,Private Securities Litigation Reform Act ,Risk Factors ,Additional Information Will Be Filed ,Investor Relations ,Company Support ,Purchase Agreement ,Rights Agreement ,Press Release ,Page Interactive Data File ,Executive Chairman ,Effective Time ,Capital Stock ,Required Filings ,Leased Real ,Legal Conditions ,Closing Directors ,Parent Support ,Restated Certificate ,Equityholder Representative ,Parent Board ,Contemplated Transactions ,Disinterested Stockholders ,Parent Stockholder Matters ,Treasury Regulations ,Parent Stockholders ,Business Day ,Constituent Corporations ,Trade Center ,Surviving Corporation ,Merger Constituent Corporations ,Merger Constituent ,Treasury Stock ,Company Common ,Dissenting Shares ,Business Days ,Payment Certificate ,Closing Indebtedness ,Transfer Agent ,Parent Common Stock ,Per Share ,Parent Common ,Allocation Schedule ,Further Ownership Rights ,Governmental Entity ,Pro Rata Share ,Tax Law ,Equity Interests ,Equity Interest ,Organizational Documents ,Delaware Secretary ,End Financials ,Most Recent Balance Sheet Date ,Year End Financials ,Interim Financials ,Ordinary Course ,Tax Returns ,Tax Return ,Recent Balance Sheet ,Call Taxes ,Treasury Regulation ,Patent Rights ,United States Patent ,Intellectual Property ,Company Disclosure ,Company Licensed Intellectual ,Company Intellectual ,Internal Systems ,License Agreement ,Diligence Obligations ,Most Recent Balance ,Legal Proceeding ,Environmental Laws ,Environmental Law ,Environmental Concern ,Service Providers ,Employee Benefit ,Employee Benefit Plan ,Foreign Corrupt Practices Act ,Economic Cooperation ,Development Convention Against Bribery ,Foreign Public Officials ,International Business Transactions ,Bribery Laws ,Anti Bribery Laws ,Regulated Product ,Federal Regulations ,Company Regulated ,Institutional Review Board ,Regulatory Authorities ,Regulated Products ,Untrue Statements ,Material Facts ,Illegal Gratuities ,Final Policy ,Application Integrity ,Generic Drug Enforcement Act ,Federal Health Care Program ,General Services Administration ,Award Management ,Accountability Act ,Individually Identifiable Health Information ,Breach Notification ,Unsecured Protected Health Information ,Each Company Equityholder ,Investor Questionnaire ,Investor Questionnaires ,Parent Disclosure Schedule ,Parent Material Adverse Effect ,Parent Preferred Stock ,Preferred Stock ,Parent Material Adverse ,Neither Parent ,Closing Period ,Acquisition Proposal ,Acquisition Inquiry ,Acquisition Transaction ,Required Parent Stockholder Vote ,Superior Offer ,Confidentiality Agreement ,Proxy Statement ,Definitive Proxy ,Beach Party ,Definitive Proxy Statement ,Stockholder Matters ,Board Recommendation ,Parent Board Recommendation ,Board Adverse Recommendation Change ,Parent Board Adverse Recommendation Change ,Permitted Alternative Agreement ,Determination Notice ,Parent Change ,New York City ,Written Consents ,Antitrust Laws ,Registration Statement ,Required Parent Stockholder ,Parent Certificate ,Proprietary Information ,Written Consent ,California Civil Code ,Such Tax Returns ,Transfer Taxes ,Tax Sharing ,Call Tax ,For United States ,Post Closing Employee Arrangements ,Outside Date ,Termination Fee ,Any Company Termination Fee ,Wall Street Journal ,Disinterested Stockholder Approval ,Base Shares ,Hart Scott Rodino Antitrust Improvements Act ,Sherman Antitrust Act ,Clayton Antitrust Act ,Federal Trade Commission Act ,Comprehensive Environmental Response ,Liability Act ,Internal Revenue Code ,Chief Financial Officer ,Common Stock ,Disclosure Schedule ,Financial Statements ,Licensed Intellectual Property ,Material Adverse Effect ,Owned Intellectual Property ,Intellectual Property Registrations ,Source Code ,Istock Plan ,Stockholder Approval ,Transaction Expenses ,Disclosure Agreement ,Delaware General Corporation Law ,Benefit Plan ,Employee Retirement Income Security Act ,Property Registrations ,Federal Insecticide ,Rodenticide Act ,Resource Conservation ,Recovery Act ,Most Recent Balance Sheet ,Recent Balance Sheet Date ,Source Materials ,Public License ,General Public License ,Mozilla Public License ,Open Source Initiative ,Closing Stock Price ,Support Agreement ,Public Company Accounting Oversight ,Alternative Agreement ,Closing Tax Period ,Grata Share ,Parent Stockholder Vote ,Disinterested Stockholder ,United States Securities ,Corporation Certificate ,American Stock Transfer ,United States Treasury ,Merger Sub ,York City ,Cutler Pickering Hale ,Chief Executive ,Parent Support Agreement ,Merger Agreement ,Constructive Sale ,Expiration Date ,Transfer Shares ,Transferred Shares ,Stockholder Capacity ,Appraisal Rights ,Relevant Provisions ,Family Members ,Family Member ,Restricted Period ,Rata Release ,Undersigned Shares ,Superior Court ,Purchase Price ,Covered Person ,Adverse Effect ,Nasdaq Global ,Trading Market ,Nasdaq Listing Rule ,Principal Trading Market ,Trading Day ,Nasdaq Global Select Market ,Nasdaq Capital Market ,Instructions Notice ,Aggregate Purchase Price ,Wire Instructions Notice ,Good Standing ,Material Adverse ,Annual Report ,Transaction Documents ,Restated Investor Rights Agreement ,Electronic Data Gathering ,Good Laboratory Practices ,Nasdaq Continued Listing ,Directed Selling Efforts ,Investment Company Act ,Anti Money Laundering ,Combating Bribery ,Corrupt Practices Act ,Patriot Act ,Bank Secrecy Act ,Financial Action Task Force ,Money Laundering ,Disqualification Event ,Such Investor ,Unless Investor ,Defense Production Act ,Confidentiality Prior ,Short Sales ,Government Recommendation ,Related Parties ,Related Party ,Additional Shares ,Aggregate Purchase ,Effect Closing ,Investor Majority ,Registrable Securities ,Trading Days ,Depository Trust ,Each Investor ,Confidentiality After ,Share Numbers ,Transaction Document ,Managing Member ,Samsara Biocapital ,General Partner ,Healthcare Fund ,Track Biotechnology Master Fund ,Back Shares ,Registration Statements ,Effectiveness Deadline ,Liquidated Damages ,Merger Shares ,Registrable Security ,Termination Date ,Such Registration Statement ,Qualification Date ,Shelf Registration Statement ,Allowed Delay ,Maintain Effectiveness ,Registration Liquidated Damages ,Maintenance Failure ,Effectiveness Liquidated Damages ,Effectiveness Period ,Cut Back Shares ,Restriction Termination Date ,Qualification Deadline ,Availability Date ,Quarterly Report ,Diligence Review ,Required Investors ,Restated Investors ,New Holder ,Selling Stockholder Questionnaire ,Presale Registration ,Full Legal Name ,Selling Stockholder ,Registered Holder ,Beneficial Ownership ,Company Owned ,Resale Registration Statement ,Beneficial Holding ,Controlling Entity ,Controlling Entities ,Securities Act Rules Compliance ,Disclosure Interpretations ,Chief Counsel ,Therapeutics Announces Agreement ,Acquire Tenet Medicines ,Deep Track Capital ,Janus Henderson Investors ,Chief Business ,Scotch Plains ,Looking Statements This ,Regulations X ,Market Data This ,Solicitation This ,Additional Information ,Solicitation Eliem ,Overview Eliem Therapeutics ,Rationale Competitive Landscape ,Differentiation Clinical Proof Of Concept ,Outlook Executive ,Moa Lead Indication ,Pre Clinical Phase ,Memoryb Plasma ,Autoantibody Secreting Cells ,Hypothesize That Depletion ,Expressing Plasmablasts ,Plasma Cells Can Potentially Lead ,Improved Clinical Benefit ,Clinical Response ,Systemic Lupus Erythematosus ,Membranous Nephropathy ,Immune Thrombocytopenia ,Myasthenia Gravis ,Systemic Sclerosis ,Diffuse Largeb Cell Lymphoma ,Vitrob Cell Potency ,Clinical Profile ,Membranous Nephropathy Preliminary Phase ,Dose Escalation Scheme ,Complete Remission ,Partial Remission ,Prior Studies ,Third Parties Showed Profound Impact ,Cytokine Release Syndrome ,Year End Deal ,Proposed Acquisition The ,Proposed Private Placement The ,Proposed Combined Company The ,Tenet Medicines Merger ,Investor Section ,Safe Harbor ,Deep Track ,